TICKERNERD
Menu
QDELQDELHealthcare · Medical Devices

QDEL Stock Forecast: QuidelOrtho Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$12
−3.05% on the day

The 3 Wall Street analysts covering QuidelOrtho Corp. hold a median 12-month price target of $12 — +1.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$807.8M
Ticker Nerd rank
35 / 100
Median analyst target
$12
Analysts covering
3
Revenue$630.9M+2.8% y/y
Operating income−$15.3M
Net income−$92.9M
Free cash flow−$136.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.4%
1M
−15.8%
YTD
−58.8%
1Y
−60.7%
From 52W high
−66.7%
From 52W low
+18.3%
$10
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QDEL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores QuidelOrtho Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Value
84
Size
47
Quality
46
Volatility
39
Revisions
35
Issuance
32
Growth
25
Momentum
14

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QDEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QDEL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26QDELHigh $20Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
1 Buy1 Hold1 Sell
Low $12Median $12High $20

The green dot is the last close — the median target sits +1.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
8 July 2026CitigroupMaintainsNeutral$13 → $18
1 July 2026JP MorganMaintainsUnderweight$11 → $12
7 May 2026JefferiesDowngradeHold—
6 May 2026CitigroupMaintainsNeutral—
10 Apr 2026UBSMaintainsNeutral—
12 Feb 2026CitigroupMaintainsNeutral—
21 Jan 2026UBSMaintainsNeutral—
7 Nov 2025JP MorganMaintainsUnderweight—
6 Nov 2025UBSMaintainsNeutral—
7 Oct 2025CitigroupDowngradeNeutral—
7 Aug 2025UBSMaintainsNeutral—
6 Aug 2025CitigroupMaintainsBuy—
8 May 2025JefferiesUpgradeBuy—
8 May 2025UBSMaintainsNeutral—
21 Apr 2025JP MorganMaintainsUnderweight—
13 Feb 2025RBC CapitalMaintainsOutperform—
13 Feb 2025UBSMaintainsNeutral—
11 Dec 2024CitigroupUpgradeBuy—
10 Dec 2024JefferiesInitiatesHold—
19 Sept 2024UBSUpgradeNeutral$42 → $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QDEL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

QDEL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, QuidelOrtho Corp. returned −60.7% against +17.5% for the S&P 500, dividends included.

QDEL vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26QDELS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QDEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−59.6%
Analysts raising
0
Analysts cutting
1
Fundamentals

QuidelOrtho Corp. (QDEL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
0.3×

Cheaper than 89% of US stocks

Price / book
0.5×

Cheaper than 86% of US stocks

EV / EBITDA
7.8×

Cheaper than 46% of US stocks

Growth & margins
Revenue growth (YoY)
2.8%

Higher than 34% of US stocks

Earnings growth (YoY)
2.8%

Higher than 39% of US stocks

Gross margin
43.3%

Higher than 54% of US stocks

Operating margin
−2.1%

Higher than 30% of US stocks

Net margin
−39.2%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−45.9%

Higher than 22% of US stocks

Return on assets
0.4%

Higher than 45% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

QuidelOrtho Corp. (QDEL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • QuidelOrtho Corp. has a market value of $807.8M and an enterprise value of $3.8B.

  • Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter grew 2.8% year on year.

  • Net income over the same four quarters: −$1.0B, a −39.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−15.41.

  • Free cash flow in the twelve months to 30 June 2026: −$211.2M.

  • Shares outstanding: 68.3M.

  • Trailing P/E: −0.7×; forward P/E: 8.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • QuidelOrtho Corp. employs 6,500 people — $411K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

QDEL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
QDELQuidelOrtho Corp.$807.8M
35
SIBNSI-BONE, Inc.$811.8M
74
AVRAnteris Technologies Global Corp.$811.9M
22
AHCOAdaptHealth Corp.$823.6M
43
VREXVarex Imaging Corp.$773.8M
80
INMDInMode Ltd.$856.5M
76
CBLLCeribell, Inc.$876.6M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own QuidelOrtho Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QDEL news & analysis

Faster Answers, Better Decisions: ADLM 2026 Highlights

PRNewsWire · 27 Aug 2026positive

QuidelOrtho released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 ADLM Annual Conference. Hosted by Stephanie Kleewein, the episode showcases three presentations on faster molecular diagnostic results, improved antibiotic stewardship, and accelerated cardiovascular assessment.

Why it matters — The episode highlights QuidelOrtho's diagnostic innovations and conference presence, offering QDEL watchers insight into the company's focus areas in molecular diagnostics, antibiotic stewardship, and cardiovascular testing.

QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns

Zacks Investment Research · 17 Aug 2026negative

QuidelOrtho cut its 2026 outlook, reflecting deeper risks in its China business and respiratory product line. The company also faces pressure from cash use and rising debt, though its core growth remains resilient.

Why it matters — A QDEL watcher would care because the reduced 2026 guidance signals heightened China and respiratory-related headwinds alongside growing financial pressure on cash and debt.

Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?

Zacks Investment Research · 17 Aug 2026neutral

Zacks examines QuidelOrtho's outlook, noting resilient core growth and a $50 million cost-reduction plan provide support, while China weakness, cash usage, and heavy debt keep the near-term case cautious.

Why it matters — QDEL watchers would care because the report highlights a balance between supportive domestic growth and cost measures against ongoing headwinds from China and the company's debt burden.

QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?

Zacks Investment Research · 17 Aug 2026neutral

QuidelOrtho shares rallied 31.7% over three months, supported by resilient core growth and cost savings. However, weakness in China, lower guidance, and high debt levels could weigh on further gains.

Why it matters — QDEL watchers would care because the stock's strong recent rally is offset by China weakness, reduced guidance, and elevated debt that may limit future upside.

QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered

Zacks Investment Research · 10 Aug 2026negative

QuidelOrtho reported Q2 earnings and revenue that beat analyst estimates. However, the company lowered its 2026 outlook, citing persistent weakness in China and a softer respiratory testing environment.

Why it matters — A QDEL watcher would note that while the quarter exceeded estimates, the cut to 2026 guidance signals headwinds in two key areas of the company's business.

FAQ

Frequently asked questions about QDEL stock

What is the QDEL stock price forecast for 2026-2027?

The 3 Wall Street analysts covering QuidelOrtho Corp. have a median 12-month price target of $12, with estimates ranging from $12 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QDEL stock a buy right now?

Of the 3 analysts covering QuidelOrtho Corp., 1 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks QuidelOrtho Corp. 35 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QDEL?

As at 12 Sept 2026, QuidelOrtho Corp. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will QDEL stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +1.9% from the last close, and Ticker Nerd's factor model ranks QuidelOrtho Corp. 35 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QDEL stock forecast for 2030?

No analyst covering QuidelOrtho Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QDEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $20 over the next 12 months.

How has QDEL stock performed over the past year?

QuidelOrtho Corp. returned -60.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does QuidelOrtho Corp. do?

QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-care testing, labs, and transfusion medicine.

What is the latest news on QDEL?

The most recent item we track (PRNewsWire, 27 Aug 2026): "Faster Answers, Better Decisions: ADLM 2026 Highlights". QuidelOrtho released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 ADLM Annual Conference. Hosted by Stephanie Kleewein, the episode showcases three presentations on faster molecular diagnostic results, improved antibiotic stewardship, and accelerated cardiovascular assessment.

Company

About QuidelOrtho Corp.

QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-care testing, labs, and transfusion medicine. Its offerings are designed to support disease detection, monitoring, and clinical decision-making in settings ranging from hospitals and reference laboratories to blood banks and other care environments. QuidelOrtho serves a global market and plays an important role in providing tools that help clinicians identify infections, manage chronic conditions, and support transfusion safety. Headquartered in San Diego, California, QuidelOrtho Corporation combines broad diagnostic expertise with a diversified portfolio that addresses both routine and specialized testing needs in modern healthcare.

CEO Mr. Brian J. Blaser · 6,500 employees · United States · https://www.quidelortho.com